PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Gynecologic and Obstetric Investigation1 citationsOpen Access

Prognostic Impact of Estrogen and Progesterone Receptor Expression Across Histological Subtypes and Clinical Factors in Epithelial Ovarian Cancer

View Full Paper
KGKhayal GasimliAWAndrea WilkeISIryna Schmeil

Key Points

  • High expression of estrogen and progesterone receptors correlated with specific histological subtypes in ovarian cancer.
  • Patients with weak progesterone receptor expression had better survival rates compared to those with strong expression.
  • Median progression-free survival was notably better in patients with low progesterone receptor expression.
  • No significant effect on overall survival was found related to estrogen receptor presence across the entire cohort.

Abstract

Objective. Epidemiological and in vitro studies of epithelial ovarian cancer (OC) strongly suggest a link between hormone receptor (HR) expression, tumorigenesis, and survival. Antihormonal therapies have shown antitumor activity in OC, both alone and combined with other treatments. The primary objective of this study is to examine the expression patterns of estrogen- and progesterone receptors (ER and PR) in OC across different histological subtypes and assess their prognostic value in disease progression. Design. Retrospective analysis of data from 164 patients who received primary treatment at University Hospital Frankfurt between January 1999 and December 2019. Materials, Setting, Methods. The expression of both hormone receptors was determined through immunostaining of tissue samples and evaluated using the immunoreactive score (IRS) according to Remmele and Stegner. Correlation and survival analyses evaluated the prognostic and predictive significance of HR expression. Results. The correlation between ER and PR expression with histological subtypes was significant (p=0.002 and p=0.013, respectively). Strong ER and PR expression was more common in HGSC, LGSC, and EC, while low PR expression was linked to higher tumor grading (p=0.032). Notably, CCC patients with weak PR expression had better survival rates than those with strong PR expression (p=0.025). The difference in OS between ER-positive and ER-negative patients was minimal (55 vs. 51 months; p=0.906). Median PFS and OS were slightly better in cases with weak PR expression (24 and 58 months) compared to strong PR expression (19 and 53 months; p=0.797 and p=0.45, respectively). In cases with strong ER expression and suboptimal debulking (TR >1 cm), disease recurrence was delayed (median PFS: 8 vs. 14 months; p=0.038), a difference not seen after optimal debulking or in overall OS. Limitations. This single-center, retrospective study limits generalizability. We could not distinguish PR isoforms or assess ER/PR ratios or interactions, limiting molecular insight. Conclusion. ER and PR expression did not demonstrate a significant overall impact on survival in the entire cohort. However, the expression patterns and associated prognosis of ER and PR differed significantly depending on histological subtypes and clinical factors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gasimli et al. (2025) studied this question.

synapsesocial.com/papers/68c1afd354b1d3bfb60e821ahttps://doi.org/10.1159/000547773
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of hormone receptor-based pathological features with prognosis in high-grade serous ovarian carcinoma: a retrospective cohort study and nomogram construction2026
  2. 2Estrogen and progesterone receptor expression: Impacts on platinum sensitivity and survival outcomes in high‐grade serous ovarian cancer2024
  3. 3Prevalence and Correlation of Age, Menopausal Status, Parity, FIGO Stage, and CA-125 Level with Estrogen and Progesterone Receptor Expression in High-Grade Serous Ovarian Cancer at Dr. Soetomo General Hospital2025
  4. 4Immunohistochemical Expression of Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor Type 2/neu, and S-100 in Epithelial Ovarian Tumors: Correlation with Clinicopathological Parameters2026
  5. 5Low androgen/progesterone or high oestrogen/androgen receptors ratio in serous ovarian cancer predicts longer survival2024 · 3 citations